Investigation of LHRH Receptor Involvement in Melanoma Growth and Progression

  • M. Montagnani Marelli
  • R. M. Moretti
  • P. Limonta
Conference paper


The hypothalamic decapeptide luteinizing hormone-releasing hormone (LHRH) is the prime controller of reproductive function (Fink, 1988). It performs this function, after being secreted from the hypothalamus into the hypophysial portal circulation, by binding and activating specific receptors on gonadotrophs (Stojilkovic et al, 1994).


Melanoma Cell Cutaneous Malignant Melanoma LHRH Agonist Reverse Transcription Polymerase Chain Reaction Analysis LHRH Analogue 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Albino A.P., Reed J.A. and McNutt N.S. (1997). Molecular biology of cutaneous malignant melanoma. In Cancer Principles and Practice of Oncology, 5th edn, eds. De Vita V.T., Hellman S., Rosenberg S.A. Philadelphia, Lippincott-Raven.Google Scholar
  2. Breslow A. (1978). The surgical treatment of stage I cutaneous melanoma. Cancer Treat Rev, 5, 195–198.PubMedCrossRefGoogle Scholar
  3. Chatzaki E., Bax C.M.R., Eidne K.A., Anderson L., Grudzinskas J.G. and Gallagher C.J. (1996). The expression of gonadotropin releasing hormone and its receptor in endometrial cancer and its relevance as an autocrine growth factor. Cancer Res, 56, 2055–2065.Google Scholar
  4. Conn P.M. and Crowley W.F. Jr. (1994). Gonadotropin-releasing hormone and its analogs. Ann Rev Med, 45, 391–405.Google Scholar
  5. Danny W.A. and Wilson W.R. (2000). Tirapazamine: a bioreductive anticancer drug that exploit tumor hypoxia. Expert Opin Investig Drug, 9, 2889–2901.CrossRefGoogle Scholar
  6. Dondi D., Limonta P., Moretti R.M., Montagnani Marelli M., Garattini E. and Motta M. (1994). Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory loop. Cancer Res, 54, 4091–4095.PubMedGoogle Scholar
  7. Dondi D., Moretti R.M., Montagnani Marelli M., Pratesi G., Polizzi D., Milani M., Motta M. and Limonta P.(1998). Growth inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer, 76, 506–511.PubMedCrossRefGoogle Scholar
  8. Emons G. and Schally A.V. (1994). The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecologi cal cancers. Hum Reprod, 9, 1364–1379.PubMedGoogle Scholar
  9. Emons G., Ortmann O., Becker M., Irmer G., Springer B., Laun R., Holzel E, Schulz K.D. and Schally A.V. (1993). High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res, 54, 5439–5446.Google Scholar
  10. Emons G., Weiss S., Ortmann O., Grundker C. and Schulz K.D. (2000). LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol, 142, 665–670.PubMedCrossRefGoogle Scholar
  11. Fink G. (1988). Gonadotropin secretion and its control. In The Physiology of Reproduction, eds. Knobil E. and Kneill J.D., pp. 1349-1377. NewYork, Raven Press.Google Scholar
  12. Halaban R. (1996). Growth factors and melanoma. Semin Oncol, 23, 673–681.PubMedGoogle Scholar
  13. Herlyn M., Clark W.H., Rodeck U., Mancianti M.L., Jambrosic J. and Koprowski H. (1987). Biology of tumor progression in human melanocytes. Lab Invest, 56, 461–474.PubMedGoogle Scholar
  14. Hofmann U.B., Westphal J.R., van Muijen G.N.P. and Ruiter D.J. (2000). Matrix metalloproteinases in human melanoma. J Invest Dermatol, 115, 337–344.PubMedCrossRefGoogle Scholar
  15. Hwu W.J. (2000). New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. Oncology, 14, 25–28.PubMedGoogle Scholar
  16. Imai A., Ohno T., Iida K., Fuseya T., Furui T. and Tamaya T. (1994). Gonadotropin-releasing hormone receptors in gynecological tumors. Cancer, 74, 2555–2561.PubMedCrossRefGoogle Scholar
  17. Kakar S.S., Musgrove L.C., Devor D.C., Sellers J.C. and Neill J.D. (1992).Cloning, sequencing and expression of human gonadotropin-releasing hormone (GnRH) receptor. Biochem Biophys Res Commun, 189, 289–295.PubMedCrossRefGoogle Scholar
  18. Kakar S.S., Grizzle W.E. and Neill J.D. (1994). The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol, 106, 145–149.PubMedCrossRefGoogle Scholar
  19. Kalra S.P. (1993). Mandatory neuropeptide-steroid signaling for the preovulatory luteinizing hormone-releasing hormone discharge. Endocr Rev, 14, 507–538.PubMedGoogle Scholar
  20. Karande A.A., Rajeshwari K., Schol D.J. and Hilgers J.H.M. (1995). Establishment of immunological probes to study human gonadotropin-releasing hormone receptors. Mol Cell Endocrinol, 114, 51–56.PubMedCrossRefGoogle Scholar
  21. Kottler M.L., Starzec A., Carre M.C., Lagarde J.P., Martin A. and Counis R. (1997). The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Int J Cancer, 71, 595–599.PubMedCrossRefGoogle Scholar
  22. Lazar-Molnar E., Hegyesi H., Toth S. and Falus A. (2000). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine, 12, 547–554.PubMedCrossRefGoogle Scholar
  23. Limonta P., Dondi D., Moretti R.M., Maggi R. and Motta M. (1992). Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab, 75, 207–212.PubMedCrossRefGoogle Scholar
  24. Limonta P., Dondi D., Moretti R.M., Fermo D., Garattini E. and Motta M. (1993). Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab, 76, 797–800.PubMedCrossRefGoogle Scholar
  25. Lu C. and Kerbel R.S. (1994). Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Curr Opin Oncol, 6, 212–220.PubMedCrossRefGoogle Scholar
  26. Mackie R.M. (1998) Incidence, risk factors and prevention of melanoma. Eur J Cancer, 34 (Suppl 3), S3-S6.PubMedCrossRefGoogle Scholar
  27. Meyer T. and Hart I.R. (1998).Mechanisms of tumor metastasis. Eur J Cancer, 34, 214–221.PubMedCrossRefGoogle Scholar
  28. Natali P.G., Nicotra M.R., Bartolazzi A., Cavaliere R. and Bigotti A. (1993). Integrin expression in cutaneous malignant melanoma: associ ation of the α3/β1 heterodimer with tumor progression. Int J Cancer, 54, 68–72.PubMedCrossRefGoogle Scholar
  29. Oikawa M., Dargan C., Ny T. and Hsueh A.J.W. (1990). Expression of gonadotropinreleasing hormone and prothymosin-a messenger ribonucleic acid in the ovary. Endocrinology 127, 2350–2356.PubMedCrossRefGoogle Scholar
  30. Parkin D.M., Pisani P. and Ferlay J. (1999). Global cancer statistics. CA Cancer J Clin, 49, 33–64.PubMedCrossRefGoogle Scholar
  31. Schally A.V. (1994). Hypothalamic hormones from neuroendocrinology to cancer therapy. Anticancer Drugs, 5, 115–130.PubMedCrossRefGoogle Scholar
  32. Shih I.M. and Herlyn M. (1993). Role of growth factors and their receptors in the development and progression of melanoma. J Invest Dermatol, 100, S196–S203.Google Scholar
  33. Shih I.M. and Herlyn M. (1994). Autocrine and paracrine roles for growth factors in melanoma. In Vivo, 8, 113–123.PubMedGoogle Scholar
  34. Stojilkovic S.S., Reinhart J. and Catt K.J. (1994).Gonadotropin-releasing hormone receptors. Structure and signal transduction pathways. Endocr Rev, 15, 462–499.PubMedGoogle Scholar
  35. Stojilkovic S.S. and Catt K.J. (1995). Expression and signal transduction pathways of gonadotropin releasing hormone receptors. Recent Prog Horm Res, 30, 161–205.Google Scholar
  36. van Groeninghen JC, Kiesel L, Winkler D and Zwirner M (1998). Effects of luteinizing hormone-releasing hormone on nervous-system tumours. Lancet, 352, 372–373.PubMedCrossRefGoogle Scholar
  37. Wormald PJ, Eidne KA and Millar RP (1985). Gonadotropin-releasing hormone receptors in human pituitary: ligand structural requirements, molecular size, cationic effects. J Clin Endocrinol and Metab, 61, 1190–1194.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • M. Montagnani Marelli
  • R. M. Moretti
  • P. Limonta

There are no affiliations available

Personalised recommendations